KVT-Study Group

KVT-Studiengruppe is a specialized clinical research organization and scientific network based in Germany, primarily focused on neurology and Multiple Sclerosis (MS). The group is renowned for managing large-scale, long-term observational studies and registries that generate high-quality Real-World Evidence (RWE) for neurological therapies. Notable projects include the PANGAEA and PANGAEA 2.0 studies, which have tracked thousands of patients treated with fingolimod over several years. By integrating clinical research into routine medical care, KVT-Studiengruppe provides pharmaceutical partners with critical data on drug safety, effectiveness, and patient-reported outcomes in real-world settings. The organization utilizes advanced digital health tools to enhance data collection and patient monitoring. Based in Dresden, it collaborates closely with academic institutions and major pharmaceutical companies to bridge the gap between clinical trials and daily medical practice.